Daniel W. Chan, Ph.D., DABCC, FACB

Professor, Pathology, Oncology, Urology, and Radiology
Director, Clinical Chemistry Division and Co-Director, Pathology Core Lab.
Director, Center for Biomarker Discovery

The Johns Hopkins University School of Medicine
Appointments: (410) 955-2674

Email: dchan@jhmi.edu

Fax: (410) 287-6388

The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. His work has demonstrated the importance of analytical methodologies for tumor markers, endocrine or clinical chemistry assays to determine the clinical outcomes of a patient's disease process. He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, breast and ovarian cancer biomarkers. He has edited and written five books on immunoassay, immunoassay automation, diagnostic endocrinology, and tumor markers. Dr. Chan has published over 200 articles including the tumor markers chapters in the Tietz Textbook of Clinical Chemistry and in Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, which he also co-edited.

Dr. Chan is actively involved in the Human Proteome Organization (HUPO) and its Plasma Proteome Initiative. He serves as chairman of a HUPO committee responsible for the development of reference specimens for a global comprehensive study of the human proteome.



  • 1968-1972
    • B.A.
      University of Oregon, Eugene, Oregon
      Biology major, Chemistry minor.
      Senior Research - Enzymology (Dr. S. A. Bernhard), Univ. of Oregon
  • 1972-1976
    • Ph.D.
      State University of New York at Buffalo, Buffalo, N.Y.
      Biochemistry major, Clinical Chemistry minor.
      Ph.D. Thesis (Dr. W. R. Slaunwhite, Jr.)


  • 1976-1977

      Teaching & Research Instructor - Department of Biochemistry,
      State University of New York at Buffalo.
      Postdoctoral training in Clinical Chemistry, Dr. Max Chilcote,
      Erie County Laboratories, Meyer Hospital, Buffalo, New York.
      (American Board of Clinical Chemistry approved program.)


Licensure & Certifications

American Board of Clinical Chemistry, 1980.


  Free access to abstracts at PubMed


  1. Chan D.W. The development of an affinity chromatography for the purification of human transcortin and its steroid binding characteristics. Ph.D. Thesis, State University of New York at Buffalo, 1976.
  2. Chan D.W. and Slaunwhite W.R., Jr. R5020 binding to pure human transcortin and albumin. J. Clin. Endocrin. & Metab. 44: 983 985, 1977.
  3. Chan D.W., Sharma M., and Slaunwhite W.R., Jr. The chemistry of human transcortin. I. Improved affinity matrices for the purification of transcortin. Arch. Biochem. Biophy. 182: 197 202, 1977.
  4. Chan D.W. and Slaunwhite W.R. , Jr. The chemistry of human transcortin. II. The effects of pH, urea, salt and temperature on the binding of cortisol and progesterone. Arch. Biochem. Biophy. 182: 437 442, 1977.
  5. Yu L., Pragay D.A., Chan D.W., and Wicher K. Biochemical parameters of normal rabbit serum. Clin. Biochem. 12: 83 87, 1979.
  6. Chan D.W., Rock R.C., and Wiegand N.J. Determination of bilirubin in pediatric samples: A re examination of the discrepancy between spectrophotometric and chemical methods. Clin. Biochem. 12: 184 185, 1979.
  7. Chan D.W. and Derkac M. An assessment of STAT TEK: A reagent strip method for glucose determination. Clin. Biochem. 13: 60 61, 1980.
  8. Perlstein M., Chan D.W., and Bill M.J. Parallelism: A useful tool for troubleshooting. The Ligand Quarterly 3: 34 36, 1980.
  9. Chan D.W., Bill M.J., and Rosenshein N. Specific binding proteins for human chorionic gonadotrophin in a patient with trophoblastic disease. Amer. J Clin. Path . 76: 214 216, 1981.
  10. Chan D.W. Estrogen assays in the monitoring of pregnancy. The Ligand Review 3, No. 1, 42 49, 1981.
  11. Belizan J.M., Villar J., Zalazar A., Rojas L., Chan D.W., and Bryce G.F. Preliminary evidence of the effect of calcium supplementation on blood pressure in normal pregnant women. Am. J. Obstet. & Gynec. 146: 175 180, 1983.
  12. Chan D.W., Waud J.M., and Hsu T.H. Clinical assessment of a radioimmunoassay for free thyroxine using a modified tracer. J. Nucl. Med. 24: 498 504, 1983.
  13. Waud J.M., Chan D.W., Drew H., Taylor E., Stem J., Oropeza M., Sucupira M.S., Graham D., Coyle J., and Niebyl J. Clinical evaluation of two direct procedures for free thyroxin and of free thyroxin index determined nonisotopically and by measuring thyroxin binding globulin. Clin. Chem. 29: 1908 1911, 1983.
  14. Chan D.W., Waud J.M., Taylor E., Stem J., Drew H., Oropeza M., Sucupira M.S. Meaning of serum free thyroxin values in nonthyroidal illnesses: Seven methods compared. Clin. Chem. 29: 2091 2093, 1983.
  15. White J.K. and Chan D.W. Evaluation of Beckman Electrolyte 2 Analyzer using ion selective sodium and potassium electrodes. J. Clin. Lab. Autom. 4: 23 28, 1984.
  16. Chan D.W. Nonthyroidal illness: Performance of free T4 methods. J. Clin. Immunoassay 7: 206 211, 1984.
  17. Chan D.W., Taylor E., Frye R., Blitzer R.L. Immunoenzymetric assay for creatine kinase MB with subunit specific monoclonal antibodies compared with immunochemical method and electrophoresis. Clin. Chem. 31: 465 469, 1985.
  18. Drew H., Chan D.W., Fong P. Performance of a solid state 48 Detector gamma counter with solid phase total thyroxin and free thyroxin. J. Nucl. Medicine, 27: 1623 1626, 1986.
  19. Chan D.W., Kinzler J., Taylor E., Donovan V., Didolkar S.M. Determination of total estriol by fluorescence polarization immunoassay. J. Clin. Immunoassay, 9: 104 106, 1986.
  20. Chan D.W., Kelsten M., Rock R.C., Bruzek D. Evaluation of a monoclonal imimmunoenzymometric assay for alpha-fetoprotein. Clin. Chem. 32: 1318 1322, 1986.
  21. Chan D.W., Miao Y.C. Affinity chromatographic separation of alpha-fetoprotein variants: development of a mini column procedure and application to cancer patients. Clin. Chem. 32: 2143 2146, 1986.
  22. Chan D.W., Bruzek D.J., Oesterling J.E., Rock R.C., Walsh P.C. Prostate specific antigen as a marker for prostate cancer: comparison of a monoclonal and a polyclonal immunoassay. Clin. Chem. 33: 1916 1920, 1987.
  23. Wu A.H., Wong S., Waldron C., Chan D.W. Automated quantitative measurement of human chorionic gonadotropin: Analytical correlation between serum and urine with creatinine correction. Clin. Chem. 33: 1916 1920, 1987.
  24. Rock R.C., Chan D.W., Bruzek D., Waldron C., Oesterling J., and Walsh P. Evaluation of a monoclonal immunoradiometric assay for prostate specific antigen. Clin. Chem. 33: 2257 2261, 1987.
  25. Chan D.W. User evaluation of immunoassay for endocrine testing. Endocrinol. Metab. 6: 5 12, 1987.
  26. Chan D.W. PSA as a marker for prostatic cancer. Lab. Mgmt. 26: 35 39, 1988.
  27. Kelsten M.L., Chan D.W., Bruzek D.J., and Rock R.C. Monitoring hepatocellular carcinoma by using a monoclonal immunoenzymometric assay for alpha fetoprotein. Clin. Chem. 34: 76 81, 1988.
  28. Oesterling J.E., Chan D.W., Epstein J.I., Kimball A.W., Bruzek D.J., Rock R.C., Brendler C.B., Walsh P.C. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urology 139: 766 772, 1988.
  29. Taylor E. and Chan D.W. The measurement of amylase by a fluorescent depolarization assay on the Abbott TDx analyzer. Lab. Medicine 19:6; 371 373, 1988.
  30. Chan D.W, Oesterling J.E. PSA in the management of prostatic cancer. Check Sample ASCP. Clin. Chem. 28:3; 1 6, 1988.
  31. Chan D.W., Beveridge R.A., Bruzek D.J., Damron D.J., Bray K.R., Gaur P.K., Ettinger D.S., Rock R.C. Monitoring breast cancer with CA 549. Clin. Chem. 34: 2000 2004, 1988.
  32. Beveridge R.A., Chan D.W., Bruzek D.J., Damron D.J., Bray K.R., Gaur P.K., Ettinger D.S., Rock R.C., Shurbaji M.S., Kuhajda F.P. A new biomarker in monitoring breast cancer: CA 549. J. Clin. Onc. 6: 1815 1821, 1988.
  33. Weber J.P., Oesterling J.E., Peters C.A., Partin A.W., Chan D.W., Walsh P.C. The influence of reversible androgen deprivation on serum prostate specific antigen levels in men with benign prostatic hyperplasia. J. Urol. 141: 987 992, 1989.
  34. Shurbaji M.S., Beveridge R.A., Chan D.W., Rock R.C., Kuhajda F.P. CA 549: Immunohistochemistry and serum levels in breast carcinoma and other neoplasms. Ann. Clin. and Lab. Science, 19: 408 414, 1989.
  35. Partin A.W., Carter H.B., Chan D.W., Epstein J.I., Oesterling J.E., Rock R.C., Weber J.P., Walsh P.C. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol. 143: 747 752, 1990.
  36. Carter H.B., Partin A.W., Epstein J.I., Chan D.W., Walsh P.C. The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. J. Urology 144: 1167-1171, 1990.
  37. Chan D.W., Gao Y.M. Variants of prostate-specific antigen separated by Concanavalin A. Clin. Chem. 37: 1133-1134, 1991 (Letter).
  38. Fisher R.S., Chan D.W, Bare M., Lesser R.P. Capillary prolactin measurement for diagnosis of seizures. Annals Neurology, 29: 187-190, 1991.
  39. Green G.B., Chan D.W., Chandra N.C., Kelen G.D. Role of the laboratory in the diagnosis of myocardial injury. Critical Care Report 2: 318-30, 1991.
  40. Graham N.M., Sorensen D., Odaka N., Brookmeyer R., Chan D.W, Willett W.C., Morris S., and Saah A.J. Relationship of serum copper and zinc levels to HIV-1 seropositivity and progression to AIDS. J. Acquired Immune Deficiency Syndrome 4: 976-80, 1991.
  41. Green G.B., Hansen K.N., Chan D.W., Guerci A.D., Fleetwood D.H., Sivertson K.T., Kelen G.D. The potential utility of a rapid CK-MB assay in evaluating emergency department patients with possible myocardial infarction. Ann. Emerg. Med. 20: 954-60, 1991.
  42. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., Fozard J.L., Walsh P.C. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
  43. Kelen G.D., Green G.B., Purcell R.H., Chan D.W., Qaqish B.F., Sivertson K.T., Quinn T.C. Hepatitis B and hepatitis C in an emergency department's patients. N. Engl. J. Med. 326: 1399-404, 1992.
  44. Burnett A.L., Chan D.W., Brendler C.B., Walsh P.C. The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J. Urol. 148: 1832-34, 1992.
  45. Carter H.B, Morrell C.H., Pearson J.D., Brant L.J., Palto C.C., Metter E.J., Chan D.W., Fozard J.L., Walsh P.C. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Research 52: 3323-28, 1992.
  46. Partin A.W., Yoo J., Carter H.B., Pearson J.D., Chan D.W., Epstein J.I., Walsh P.C. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J. Urol. 150:110-114, 1993.
  47. Chan D.W. Automation of Thyroid Function Testing. Clinics in Laboratory Medicine 13: 631-644, 1993.
  48. Hsu C.D., Iriye B., Johnson T.R.B., Hong S.F., Chan D.W. Elevated circulating thrombomodulin levels in severe preeclampsia. Am. J. Obstet. Gynecol. 169: 148-9, 1993.
  49. Chan D.W. Prostate Specific Antigen as a Marker for Prostatic Cancer. Advances in Pathology and Laboratory Medicine, 6: 89-101, 1993.
  50. Chan D.W. Automated immunoassay systems: An updated review. Endocrinol. Metab. 12: 123-125, 1994.
  51. Hsu C.-D., Chan D.W., Iriye B., Johnson T.R.B., Hong S.F., Repke J.T. Elevated serum human chorionic gonadotropin as evidence of secretory response in severe preeclampsia. Am. J. Obstet. Gynecol. 170: 1135-8, 1994.
  52. Chan D.W., Beveridge R.A., Bhargava A., Wilcox P.M., Kennedy M.J., Schwartz M.K. Breast cancer marker CA 549: A multi-center study. A. J. Clin Pathology 101: 465-470, 1994.
  53. Hsu C.D., Lucas R. B.., Johnson T.R.B., Hong S.F., Chan D.W. Elevated urine thrombomodulin/creatinine ratio as evidence of endothelial cell injury in severely preeclamptic pregnancy. Am. J. Obstet. Gynecol. 171: 854-6, 1994.
  54. McDowell P.R. and Chan D.W. Congenital adrenal hyperplasia. Endocrinol. Metab. 13: 7-10,1995.
  55. Hsu C.D., Chan D.W., Johnson T.R.B., Iriye B., Hong S.F., Petri M. Plasma thrombomodulin levels in women with systemic lupus erythematosus. Am J. Perinatology 12: 27-29, 1995.
  56. Nichols J.H., Howard C., Loman K., Miller C., Nyberg D., Chan D.W. Laboratory and bedside evaluation of portable glucose meters. Am J. Clin. Path. 103: 244-251, 1995.
  57. Chan D.W. Markers for breast cancer. Endocrinol. Metab. 13: 71-73, 1995.
  58. Carter H.B., Pearson J.D., Waclawiw Z., Metter E.J., Chan D.W., Guess H.A, Walsh P.C. Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity. Urology 45: 591-6, 1995.
  59. Nelson R.S. and Chan D.W. Subclinical hyperthyroidism and atrial fibrillation. Endocrinol. Metab. 13: 167-168, 1995.
  60. Hsu C.-D., Smith C., Hong S.F., Johnson T.R.B., Gollin Y., Chan D.W. Does preeclamptic pregnancy increase fetal-maternal hemorrhage? Am J. Perinatology, 12: 205-207, 1995.
  61. Chan D.W. Clinical instrumentation (Immunoassay analyzers). Analytical Chemistry 67:519R-524R, 1995.
  62. Sokoll L.J. and Chan D.W. Assessment of vitamin K nutritional status. Endocrinol. Metab. 13: 247-249, 1995.
  63. Carter H.B., Pearson J.D., Metter E.J., Chan D.W., Andres R., Fozard J.L., Rosner W., Walsh P.C. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. The Prostate 27: 25-31, 1995.
  64. Steinberg D.M. and Chan D.W. Obesity: New ways to lose weight and keep it off. Endocrinol. Metab. 13: 347-349, 1995.
  65. Hsu C.-D., Johnson T.R.B., Hong S.F., Chan D.W. Altered circulating thrombomodulin and fibronectin levels as evidence for different degrees of vascular endothelial damage between severe and mild preeclampsia. J. Maternal-Fetal Invest. 5: 65-67, 1995.
  66. Hsu C.-D., Johnson T.R.B., Hong S.F., Chan D.W. Altered circulating thrombomodulin levels and antithrombin-III activity as evidence for varied activation of the coagulation cascade in severely versus mildly preeclamptic pregnancies. J. Maternal-Fetal Investig., 5: 140-143, 1995.
  67. Hsu, C.-D., Copel J.A., Hong S.F., Chan D.W. Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Obstet Gynecol. 86: 897-899, 1995.
  68. Sokoll L.J., Levine M.A., Chan D.W. Pseudohypoparathyroidism. Diag. Endocrin. Metab. 14: 39-41, 1996.
  69. Riopel M.A. and Chan D.W. Ovarian carcinoma and the use of serum CA-125. Diag. Endocrin. Metab. 14: 63-65, 1996.
  70. Pappalardo P.A. and Chan D.W. Molecular markers for colorectal cancer. Diag. Endocrin. Metab. 14: 179-182, 1996.
  71. Partin A.W., Piantadosi S., Subong E.N.P., Kelley C.A., Hortopan S., Chan D.W., Wolfert R.L., Rittenhouse H.G., Carter H.B. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. The Prostate (Supplement) 7:35-39, 1996.
  72. Pearson J.D., Luderer A.A., Metter E.J., Partin A.W., Chan D.W., Fozard J.L., Carter H.B. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology 48:4-9, 1996.
  73. Thiel R.P., Oesterling J.E., Wojno K.J., Partin A.W., Chan D.W., Carter H.B., Stamey T.A., Prestigiacomo A.R, Brawer M.K., Petteway J.C., Carlson G., Luderer A.A. A multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 48:45-50, 1996.
  74. Pannek J., Subong E.N.P., Jones K.A., Marschke P.L.S., Epstein J.I., Chan D.W., Carter H.B., Luderer A.A., and Partin A.W. The role of free/total prostate-specific antigen ratio in the prediction of final pathological stage for men with clinically localized prostate cancer. Urology 48:51-54, 1996.
  75. Partin A.W., Catalona W.J., Southwick P.C., Subong E.N.P., Gasior G.H., Chan D.W. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48:55-61, 1996.
  76. Silver R.I., Partin A.W., Epstein J., Chan D.W., Hutchins G., Carter H.B., Jeffs R.D., Gearhart J.P. Prostate-specific antigen in men born with bladder exstrophy. Urology 49:253-256, 1997.
  77. Ruska K.M. and Chan D.W. Urinary NMP22 and BTA: New markers for transitional cell carcinoma of the bladder. Diag. Endocrin. Metab. 15: 31-32, 1997.
  78. Baisden B.L. and Chan D.W. Carcinoid syndrome. Diag. Endocrin. Metab. 15: 33-35, 1997.
  79. Carter H.B., Partin A.W., Luderer A.A., Metter E.J., Landis P., Chan D.W., Fozard J.L., Pearson J.D. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49:379-384, 1997.
  80. Sokoll L.J. and Chan D.W. Prostate-specific antigen: Its discovery and biochemical characteristics. Urologic Clinics of North America 24:253-259, 1997.
  81. Carter H.B., Epstein J.I., Chan D.W., Fozard J.L., Pearson J.D. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277:1456-1460, 1997.
  82. Chan D.W., Beveridge R.A., Muss H., Fritsche H.A., Hortobagyi G., Theriault R., Kiang D., Kennedy B.J., Evelegh M. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with Stage II and Stage III disease. J. Clin. Onc. 15:2322-2328, 1997.
  83. Weir E.G. and Chan D.W. Homocysteine and thrombogenesis. Diag. Endocrin. Metab. 15:165-168, 1997.
  84. Sokoll L.J. and Chan D.W. Clinical Instrumentation (Immunoassay Analyzers). Analytical Chemistry, 60:203R-209R, 1997.
  85. Sokoll L.J., Chan, D.W. Clinical Applications of Artificial Neural Networks. Diag. Endocrin. Metab., Vol. 15:277-229, 1997.
  86. Hsu C.D., Copel J.A., Chan D.W. Antepartum and postpartum thrombomodulin levels in preeclamptic and normotensive pregnancies. J. Soc. Gynecol. Invest. 4: 135-137, 1997.
  87. Pannek J., Rittenhouse H.G., Evans C.L., Finlay J.A., Bruzek D.J., Cox J.L., Chan D.W., Subong E.N.P., Partin A.W. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology 50:715-721, 1997.
  88. Chan D.W. and Sokoll L.J. Prostate specific antigen: 1997 update. JIFCC, 9:120-125, 1997.
  89. Steele B.W., Witte D.L., Whitley R.J., Klee G.G., Chan D.W. The effects of modifying proficiency testing materials on thyroid function test results. Arch. Pathol. Lab. Med. 121:1241-1246, 1997.
  90. Sokoll L.J., Kroll M.H., Levine M.A., Poordad F.F., Chan D.W. Bone to total alkaline phosphatase ratios improve sensitivity and specificity of bone alkaline phosphatase immunoassays. Clin. Biochem. 30:625-629, 1997.
  91. Pound C.R., Walsh P.C., Epstein J.I., Chan D.W., Partin A.W. Radical prostatectomy as treatment for prostate-specific-antigen-detected stage T1c prostate cancer. World J. Urol. 15:373-377, 1997.
  92. Magriples U., Hsu C.D., Chan D.W., Nickless N., Copel J.A. Circulating thrombomodulin levels and clinical correlates in pregnant diabetics. Am. J. Perinatol. 14:605-608, 1997.
  93. Zhou W., Sokoll L.J., Bruzek D.J., Zhang L., Velculescu V.E., Goldin S.B., Hruban R.H. Kern S.E., Hamilton S.R., Chan D.W., Vogelstein B., Kinzler K.W. Identifying markers for pancreatic cancer by gene expression analysis. J. Cancer Epidemiology, Biomarkers & Prevention 7:109-112, 1998.
  94. Pannek J., Marks L.S., Pearson J.D., Rittenhouse H.G., Chan D.W., Shery E.D., Gormley G.J., Subong E.N.P., Kelley C.A., Stoner E., Partin A.W. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J. Urol. 159:449-453, 1998.
  95. Green G.B., Beaudreau R.W., Chan D.W., DeLong D., Kelley C.A., Kelen G.D., Use of troponin T and creatine kinase-MB subunit levels for risk stratification of emergency department patients with possible myocardial ischemia. Annals of Emerg. Med., 31:19-29, 1998.
  96. Pannek J., Rittenhouse H.G., Chan D.W., Epstein J.I., Walsh P.C., Partin A.W. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J. Urol. 159:1238-1242, 1998.
  97. Sokoll L.J. and Chan D.W. Clinical applications of the molecular forms of prostate-specific antigen. Diag. Endocrin. Metab. 16:135-147, 1998.
  98. Morris D.L., Dillon P.W., Very D.L., Ng P., Kish L., Goldblatt J.L., Bruzek D.J., Chan D.W., Ahmed M.S., Witek D., Fritsche H.A., Smith C., Schwartz D., Schwartz M.K., Noteboom J.L., Vessella R.L., Yeung K.K., Allard W.J. Bayer Immuno 1J PSA Assay: An Automated, Ultrasensitive Method to Quantitate Total PSA in Serum. J. Clin. Lab. Analysis 12:65-74, 1998.
  99. Partin A.W., Brawer M.K., Subong E.N.P., Kelly C.A., Bruzek D.J., Pannek J., Meyer G.E., Chan D.W. Prospective evaluation of percent free-PSA for early detection of prostate cancer. Prostate Ca and Prostatic Diseases. 1:197-203, 1998.
  100. Sokoll L.J. and Chan D.W. Total, free, and complexed prostate-specific antigen: Analysis and clinical utility. J. Clin. Ligand Assay 21:171-179, 1998.
  101. Miller L.R., Partin A.W., Chan D.W., Bruzek D.J., Dobs A.S., Epstein J.E., Walsh P.C. Influence of radical prostatectomy on serum hormone levels. J. Urol. 160:449-453, 1998.
  102. Sokoll L.J. and Chan D.W. Tumor markers for breast cancer. Diag. Endocrin. Metab. 16:337-352, 1998.
  103. Cheli C.D., Morris D.L., Kish L., Goldblatt J., Neaman I., Allard W.J., Yeung K.K., Wu A.H.B., Moore R., Chan D.W., Fritsche H.A., Schwartz M.K., Very D.L. Multicenter evaluation of the Bayer Immuno 1tm CA 15-3tm Assay. Clin. Chem. 44:765-777, 1998.
  104. Green G.B., Li D.J., Bessman E.S., Cox J.L., Kelen G.D., Chan D.W. The prognostic significance of troponin-I and troponin-T. Acad. Emerg. Med. 5:758-767, 1998.
  105. Lynch D.M., Rogers P.E., Love J.C., Salkas M.J., Skarphol K.A., Gross M.E., Lu M.G., Petrides V.H., Bruzek D.J., Cox J.L., Jones K.A., Kelly C.A., Chan D.W. Clinical evaluation comparing AxSYM CA 15-3, IMx, CA 15-3 and Truquant BR RIA. Tumor Biol. 19:421-438, 1998.
  106. Chan D.W., Multicentre Evaluation of the Boehringer Mannheim Elecsys 2010 Immunoassay System, Preface. Wiener Klinische Wochenschrift 110(Suppl 3)3: 1998.
  107. Uhl W., Chan D.W., Jones K., Kelley C., Assmann G., Voneckardstein A., Sagers A., Yvert J.P., Schneider A.M., Torralba A., Fuentesarderiu X., Delapresa B.G., Vives M., Greiling H., Eberle A., Neiderau C.M., Cremer P., Reiter W., Vogeser M., Neumeier D., Luppa P., Huber U. Elecsys CEA, PSA and AFP - Clinical Results of a Multicentre Evaluation. Wiener Klinische Wochenschrift 110(Suppl 3)3:51-61, 1998.
  108. Epstein J.I., Chan D.W., Sokoll L.J., Walsh P.C., Cox J.L., Rittenhouse H., Wolfert R., Carter H.B. Nonpalpable T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160:2407-2411, 1998.
  109. Van Ingen H.E., Chan D.W., Hubl W., Miyachi H., Molina R., Pitzel L., Ruibal A., Rymer J.C., Domke I. Analytical and clinical evaluation of an electrochemiluminence immunoassay for the determination of CA 125. Clin Chem 44:2530-2536, 1998.
  110. Cina S., Li D., Chan D., Boitnott J., Hruban R., Smialek J. Serum concentrations in cardiac Troponin I in sudden death: A pilot study. Am. J. Forens. Med. Path. 4:324-328, 1998.
  111. Li D.J., Sokoll L.J., Chan D.W. Automated chemiluminescent immunoassay analyzers. J. Clin. Ligand Assay 21:377-385, 1999.
  112. Sokoll L.J., Partin A.W., Nelson J.B., Chan D.W. A critical analysis of false elevations in PSA results reported with the Abbott AxSYM assay. (Letter). The Prostate 38:79-80, 1999.
  113. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999.
  114. Chan D.W. and Sokoll L.J. Prostate-specific antigen: Advances and challenges. (Editorial). Clin. Chem. 45:755-756, 1999.
  115. Chan D.W. and Sokoll L.J. Immunoassay automation at the millennium. J. Clin. Ligand Assay 22:4-5, 1999.
  116. Catalona W.J., Partin A.W., Finlay J.A., Chan D.W., Rittenhouse H.G., Wolfert R.L., Woodrum D.L. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model. Urology 54:220-224, 1999.
  117. Chan D.W., Kelley C.A., Ratliff T.L., D. D'Agostino, Ritchey J., Lamb D.J., Beck J., Lott N., et al. Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine the clinical utility of percentage of free prostate-specific antigen. Clin. Chem. 45:1863-65, 1999.
  118. Chance J.J. and Chan D.W. Making sense of biosensors. Diagn. Endocrin., Immun. & Metab. 17:3-5, 1999.
  119. Sokoll L.J. and Chan D.W. Clinical Analyzers - Immunoassays. Analyt. Chem. 71:356-362, 1999.
  120. Chan J.J. and Chan D.W. Immunoassay automation: A practical guide to system selection. Advance/Laboratory, Sept., 45-50, 1999.
  121. Rittenhouse H.G. and Chan D.W. Can complexed PSA be used as a single test for detecting prostate cancer? (Editorial). Urol. 54:4-5, 1999.
  122. Sokoll L.J., Udelsman R., Chan D.W. Intraoperative parathyroid hormone measurement. Diagn. Endocrin., Immun., & Metab. 17:295-302, 1999.
  123. Wang T.J., Linton H.J., Payne J., Rittenhouse H.G., Chan D.W., Partin A.W., Wolfert R.L., Kuus-Reichel K. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay. Hybridoma 18:535-541, 1999.
  124. Hubl W., Chan D.W., Van Ingen H.E., Miyachi H., Molina R., Filella X., Pitzel L., Ruibal A., Rymer J.C., Bagnard G., Domke I. Multicenter evaluation of the Elecsys® CA 125 II assay. Anticancer Research 19:2727-2734, 1999.
  125. Partin A.W., Catalona W.J., Finlay J.A., Wang T.J., Darte C., Tindall D. J., Young C.Y., Klee G.G., Chan D.W., Rittenhouse H.G., Wolfert R.L., Woodrum D.L. The use of human glandular kallidrein 2 (hK2) for the detection of prostate cancer. Urology 54:839-845, 1999.
  126. Allard W.J., Cheli C.D., Morris D.L., Goldblatt J., Pierre Y., Kish L, Chen Y., Dai J., Vessella R.L., Chan D.W., Schwartz M.K., Zhou Z., Yeung K.K. Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay. Int. J. Biol. Markers 14:78-83, 1999.
  127. Magriples U., Chan D.W., Bruzek D., Copel J.A., Hsu C.D. Thrombomodulin: A new marker for placental abruption. Thromb. Haemost. 81:32-34, 1999.
  128. Udelsman R., Osterman F., Sokoll L.J., Drew H., Levine M.A., Chan D.W. Rapid parathyroid hormone measurement during venous localization. Clinica Chimica Acta 295:193-198, 2000.
  129. Shih I.-M., Torrance C., Sokoll L.J., Chan D.W., Kinzler K.W., Vogelstein B. Assessing tumors in living animals through measurement of urinary ß-human chorionic gonadotropin. Nature Medicine 6:711-714, 2000.
  130. Brawer M.K., Cheli C.D., Neaman I.E., Goldblatt J., Smith C., Schwartz M.K., Bruzek D.J., Morris D.L., Sokoll L.J., Chan D.W., Yeung K.K., Partin A.W., Allard W.J. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J. Urology 163:1476-1480, 2000.
  131. Vessella R.L., Lange P.H., Partin A.W., Chan D.W., Sokoll L.J., Sasse E.A., Crawford E.D. Probability of prostate cancer detection based on results of a multicenter study using AxSYM free PSA and total PSA assays. Urology 55:909-914, 2000.
  132. Green G.B., Dehlinger E., McGrievey T.S., Li D.J., Jones K.A., Kelen G.D., Chan D.W. CK- MB isoforms for early risk stratification of emergency department patients. Clinica Chimica Acta 300:57-73, 2000.
  133. Chan D.W., Sokoll L.J. WHO first international standards for prostate-specific antigen: The beginning of the end for assay discrepancies? (Editorial). Clin. Chem. 46:1291-1292, 2000.
  134. Sokoll L.J., Witte D.L., Klee G.G., Chan D.W. Redesigned proficiency testing materials improve survey outcomes for prostate-specific antigen. Arch Pathol Lab Med 124:1608-1613, 2000.
  135. Green G.B., Skarbek-Borowski, Chan D.W., Kelen G.D. Myoglobin for early risk stratification of emergency department patients with myocardial ischemia. Acad Emerg Med 6:625-636, 2000.
  136. Laffin R.J., Chan D.W., Tanasijevic M.J., Fischer G.A., Markus W., Miller J., Matarrese P., Sokoll L.J., Bruzek D.J., Eneman J., Nelson J., Bray K.R., Huang J., Loveland K.G. Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter Access Automated Chemiluminescent Immunoassay System: A multicenter evaluation of analytical performance. Clin. Chem. 47:129-132, 2001.
  137. Wang Y., Kuhajda F.P., Sokoll L.J., Chan, D.W. Two-site ELISA for the quantitative determination of fatty acid synthase. Clinica Chimica Acta 304:107-115, 2001.
  138. Han M., Piantadosi S., Zahurak M.L., Sokoll L.J., Chan D.W., Epstein J.I., Walsh P.C., Partin A.W. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57:707-711, 2001.
  139. Denmeade S.R., Sokoll L.J., Chan D.W., Khan S.R., Isaacs J.T. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. The Prostate 48:1-6, 2001.
  140. Cook G.B., Neaman I.E., Goldblatt J.L., Cambetas D.R., Hussain M., Luftner D., Yeung K.K., Chan D.W., Schwartz MK, Allard WJ. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res. 21:1465-1470, 2001.
  141. Wang Y., Kuhajda F.P., Li J.N., Pizer E.S., Han W.F., Sokoll L.J., Chan D.W. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Letters 167:99-104, 2001.
  142. Fang J., Metter E.J., Landis P., Chan D.W., Morrell C.H., Carter H.B. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: Results from the Baltimore Longitudinal Study of Aging. Urology 58:411-416, 2001.
  143. Chance J.J., Segal J.B., Wallerson G., Kasper E., Hruban R.H., Kickler T.S., Chan D.W. Cardiac troponin-T and C-reactive protein as markers of acute cardiac allograft rejection. Clinica Chimica Acta 312:31-39, 2001.
  144. Brooks J.D., Metter E.J., Chan D.W., Sokoll L.J., Landis P., Nelson W.G., Muller D., Andres R., Carter H.B. Plasma selenium level before diagnosis and the risk of prostate cancer development. J. Urol. 166:2034-2038, 2001.
  145. Rai A.J., Chan D.W. Cancer proteomics: New developments in clinical chemistry. J. Lab Med 25:399-403, 2001.
  146. Luppa P.B., Sokoll L.J., Chan D.W. Immunosensors – principles and applications to clinical chemistry. Clinica Chimica Acta 314:1-26, 2001.
  147. Stieber P., Molina R., Chan D.W., Fritsche H.A., Beyrau R., Bonfrer J.M., Filella X., Gornet T.G., Hoff T., Jager W., van Kamp G.J., Nagel D., Peisker K., Sokoll L.J., Troalen F., Untch M., Domke I. Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay. Clin. Chem. 47:2162-2164, 2001.
  148. Rosty C., Christa L., Kuzdzal S., Baldwin W.M., Zahurak M.L., Carnot F., Chan D.W., Canto M., Lillemoe K.D., Cameron J.L., Yeo C.J., Hruban R.H., Goggins M. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated Protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Research 62:1868-1875, 2002.
  149. Haese A., Dworschack R.T., Piccoli S.P., Sokoll L.J., Partin A.W., Chan D.W. Clinical evaluation of the Elecsys total prostate-specific antigen assay on the Elecsys 1010 and 2010 systems. Clin. Chem. 48:944-947, 2002.
  150. Wright E.J., Fang J., Metter E.J., Partin A.W., Landis P., Chan D.W., Carter H.B. Prostate- specific antigen predicts the long-term risk of prostate enlargement: Results from the Baltimore Longitudinal Study of Aging. J. Urol. 167: 2484-2487, 2002.
  151. Okihara K., Cheli C.D., Partin A.W., Fritsche H.A., Chan D.W., Sokoll L.J., Brawer M.K., Schwartz M.K., Vessella R.L., Loughlin K.R., Johnston D.A., Babaian R.J. Comparative analysis of complexed prostate-specific antigen, free prostate-specific antigen, and their role in detecting prostate cancer. J. Urol. 167:2017-2023, 2002.
  152. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., and Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48:1296-1304, 2002.
  153. Wang Y.Y., Kuhajda F.P., Cheng P.(C.P.), Chee W.Y., Li T., Helzlsouer K.J., Sokoll L.J., Chan D.W. A new model ELISA, based on two monoclonal antibodies, for quantification of fatty acid synthase. J. Immunoassay & Immunochemistry 23:279-292, 2002.
  154. Taneja S.S., Hsu E.I., Cheli C.D., Walden P., Bartsch G., Horninger W., Babaian R.J., Fritsche H.A., Childs S., Stamey T.A., Sokoll L.J., Chan D.W., Brawer M.J., Partin A.W., Lepor H. Complexed prostate-specific antigen as a staging tool: Results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology 60:10-17, 2002.
  155. Sokoll L.J., Mangold L.A., Partin A.W., Epstein J.I., Bruzek D.J., Dunn W., Mohr P., Wallerson G., Chan D.W. Complexed prostate-specific antigen as a staging tool for prostate cancer: A prospective study in 420 men. Urology 60:18-23, 2002.
  156. Sokoll L.J., Bruzek D.J., Dua R., Dunn W., Mohr P., Wallerson G., Eisenberger M., Partin A.W., Chan D.W. Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology 60:24-30, 2002.
  157. Horninger W., Cheli C.D., Babaian R.J., Fritsche H.A., Lepor H., Taneja S.S., Childs S., Stamey T.A., Sokoll L.J., Chan D.W., Brawer M.K., Partin A.W., and Bartsch G. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 60:31-35, 2002.
  158. Naya Y., Stamey T.A., Cheli C.D., Partin A.W., Sokoll L.J., Chan D.W., Brawer M.J., Taneja S.S., Lepor H., Bartsch G., Childs S., Fritsche H.A., Babaian R.J. Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? Urology 60:36-41, 2002.
  159. Kim L.J., Martinez E.A., Faraday N., Dorman T. , Fleisher L.A., Perler B.A., Williams M., Chan D.W., Pronovost P.J. Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 106: 2366-2371, 2002.
  160. Rai A.J., Zhang Z., Rosenzweig J., Shih I.-M., Pham T., Fung E., Sokoll L.J., and Chan D.W. Proteomic approaches to tumor marker discovery: Identification of biomarkers for ovarian cancer. Arch. Pathol. Lab. Med. 126:1581-1526, 2002.
  161. Chang H.-W., Lee S.M., Goodman S. N., Singer G., Cho S.K.R., Sokoll L.J., Montz F.J., Roden R., Zhang Z., Chan D.W., Kurman R.J., Shih I.-M. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J. Natl. Ca. Inst. 94:1697-1703, 2002.
  162. Wians, Jr., F.H., Cheli C.D., Balko J.A., Bruzek D.J., Chan D.W., Sokoll L.J. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer. Clin Chim Acta 326: 81-95, 2002.
  163. Stieber P., Molina R., Chan D.W., Fritsche H.A., Beyrau R., Bonfrer J.M., Filella X., Gornet T.G., Hoff T., Jager W., van Kamp G.J., Nagel D., Peisker K., Sokoll L.J., Troalen F., Untch M., Domke I. Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clin Lab 49:15-24, 2003.
  164. Sokoll L.J., Chan D.W., Mikolajczyk, Rittenhouse H.G., Evans C.L., Linton H.J., Mangold L.A., Mohr P., Bartsch G., Klocker H., Horninger W., Partin A.W. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/mL total PSA range: Preliminary Analysis. Urology 61:274-276, 2003.
  165. Haese A., Vaisanen V., Finlay J.A., Pettersson K., Rittenhouse H.G., Partin A.W., Bruzek D.J., Sokoll L.J., Lilja H., Chan D.W. Standardization of two immunoassays for human glandular kallikrein 2. Clin. Chem. 49:601-610, 2003.
  166. Wang Y.Y., Cheng P.(C.P.), Chan D.W. A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 3: 243-248, 2003.
  167. Clarke W., Silverman B.C., Zhang Z., Chan D.W., Klein A.S., Molmenti E.P. Characterization of renal allograft rejection by urinary proteomic analysis. Ann. Surgery 5:660-665, 2003.
  168. Singer G., Rebmann V., Chen Y.-C., Liu H.-T., Ali S.Z., Reinsberg J., McMaster M.T., Pfeiffer K., Chan D.W., Wardelmann E., Grosse-Wilde H., Cheng C.-C., Kurman R.J., and Shih I.-M. HLA-G is a potential tumor marker in malignant ascites. Clin. Cancer Research 9:4460-4464, 2003.
  169. Partin A.W., Brawer M.K., Bartsch G., Horninger W., Taneja S.S., Lepor H., Babaian R., Childs S.J., Stamey T., Fritsche H.A., Sokoll L., Chan D.W., Thiel R.P., Cheli C.D. Complexed prostate specific antigen improves specificity for prostate cancer detection: Results of a prospective multicenter clinical trial. J. Urol. 170:1787-1791, 2003.
  170. Khan M.A., Partin A.W., Rittenhouse H.G., Mikolajczyk, Sokoll L.J., Chan D.W., Veltri R.W. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J. Urol. 170:723-726, 2003.
  171. Wang B.G., Huang H.-Y., Chen Y.-C., Bristow R.E., Kassauei K., Cheng C.-C., Roden R., Sokoll L.J., Chan D.W., and Shih I.-M. Increased plasma DNA integrity in cancer patients. Cancer Research 63:3966-3968, 2003.
  172. Clarke W., Zhang Z., Chan D.W. The application of clinical proteomics to cancer and other diseases. Clin. Chem. Lab. Med. 41:1562-1570, 2003.
  173. Park J., Sokoll L.J., Bruzek D.J., Mangold L., Gurganus R., Khan M.A., Partin A.W., Chan D.W., Veltri R.W. Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men. Clin. Prostate Cancer, 2:173-176, 2003.
  174. Naya Y, Fritsche HA, Cheli CD, Stamey TA, Bartsch G, Brawer MK, Childs S, Taneja SS, Lepor H, Partin AW, Sokoll LJ, Chan DW, Babaian RJ.   Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.  Urology 62:1058-1062, 2003. 
  175. Gretzer MB, Partin AW, Chan DW, Veltri, RW. Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI). Reviews in Urology, vol. 5 No. 2, 2003.
  176. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan  DW, Goggins M.  Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry.  Clin. Cancer Research 10:860-868, 2004.
  177. Li J, White N, Zhang Z, Rosenzweig J., Mangold LA, Partin AW, Chan DW.  Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population.  J. Urol. 171:1782-1787, 2004.
  178. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Kukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M.   Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.  Clin. Cancer Research 10:2386-2392, 2004.
  179. Rai AJ, Chan DW.   Cancer Proteomics:  Serum Diagnostics for Tumor Marker Discovery.   Ann. N.Y. Acad. Sci. 1022:286-294, 2004.
  180. Wang YY, Kuhajda FP, Li J, Finch TT, Cheng P, Koh C, Li T, Sokoll LJ, Chan DW.  Fatty acid synthase as a tumor marker:  its extracellular expression in human breast cancer.  J. Experimental Therap. & Oncol. 4:101-110, 2004.
  181. Zhang Z, Bast Jr. RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng X-Y, Berchuck A, van Haaften-Day C, Hacker NF, de Bruijn H.WA, van der Zee AGJ, Jacobs IJ, Fung ET, and Chan DW.   Three biomarkers identified from serum proteomics analysis for the detection of early stage ovarian cancer.  Cancer Research 64:5882-5890, 2004.
  182. White CN, Chan DW, and Zhang Z.  Bioinformatics strategies for proteomic profiling.  Clin. Biochem. 37:636-641, 2004. 
  183. Kunz GM Jr., and Chan DW.   The use of laser capture microscopy in proteomics research - A review.  Disease Markers 20:155-160, 2004.
  184. Gretzer MB, Chan DW, van Rootselaar CL, Rosenzweig JM, Dalrymple S., Mangold LA, Partin AW, Veltri RW.   Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.   Prostate 60:325-331, 2004.
  185. Khan MA, Sokoll LJ, Chan DW, Mangold LA, Mohr P, Mikolajczyk SD, Linton HJ, Evans CL, Rittenhouse HG, Partin AW.   Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.  Urology 64:1160-1164. 2004.
  186. Bieglmayer C, Chan DW, Sokoll L, Imdahl R, Kobayashi M, Yamada E, Lilje DJ, Luthe H, Meissner J, Messeri G., Celli A, Tozzi P, Roth HJ, Schmidt FP, Machler ML, Schuff-Werner P, Zingler C, Smitz J, Schiettecatte J, Vonderschmitt DJ, Pei P, Ng K, Ebert C, Kirch P, Wanger M, McGovern M, Stockmann W, Kuns A.   Multicentre performance evaluation of the E170 module for modular analytics.  Clin Chem Lab Med 42:1186-1202, 2004.
  187. Semmes OJ, Feng Z, Adam B-L, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava Sudhir, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L.   Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer:  I. Assessment of platform reproducibility.  Clin. Chem. 51:102-112, 2005.
  188. White C.N., Zhang Z., Chan DW.   Quality control for SELDI Analysis.   (Editorial)  Clin. Chem. Lab. Med.  43:125-126, 2005.
  189. Haese A, Vaisanen V., Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H., Sokoll LJ, Partin AW.   Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. J. Urol. 173:752-756, 2005. 
  190. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, Lin S, Zhang F, Zhang Z, Chan DW, Weinberger SR.   Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.   Int. J. Cancer. 115(5):783-9, 2005.
  191. Horowitz GL, Zaman Z, Blanckaert NJC, Chan DW, DuBois JA, Golaz O, Mensi N, Keller F, Stolz H, Klinger K, Marocchi A, Prencipe L, McLawhon RW, Nilsen OL, Oellerich M, Luthe H, Orsonneau J-L, Richeux G, Recio F, Roldan E, Rymo L, Wicktorsson A-C, Welch SL, Wieland H, Grawitz AB, Mitsumaki H, McGovern M, Ng K, Stockmann W.  MODULAR ANALYTICS:  A new approach to automation in the clinical laboratory.   J Automated Methods & Mgmt. in Chem. 1:8-25, 2005.
  192. Martinez EA, Nass CM, Jermyn RM, Rosenbaum SH, Akhtar S, Chan DW,  Malkus H, Weiss JL, Fleisher LA.   Intermittent cardiac troponin-I screening is an effective means of surveillance for a perioperative myocardial infarction.  J. Cardiothorac & Vascular Anesth. 19:577-582, 2005.
  193. Colantonio DA, Chan DW.  The clinical application of proteomics.  Clin Chimica Acta 357:151-158, 2005.
  194. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, Mehigh RJ, Cockrill SL., Scott GBI, Tammen H, Schulz-Knappe P, Speicher DW, Vitzthum F, Haab BB, Siest G, Chan DW.   HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples.  Proteomics 5:3262-3277, 2005.
  195. Rai AJ, Stemmer PM, Zhang Z, Adam B-I, Morgan WT, Caffrey RE, Podust VN, Patel M, Lim L-Y, Shipulina NV, Chan DW, Semmes OJ, Leung H-CE.   Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: Multi-institution correlation of spectra and identification of biomarkers.   Proteomics 5:3467-3474, 2005.
  196. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes J S, Kapp EA, Moritz RL, Chan DW, Rai AJ, Admon A, Aebersold R, Eng J, Hancock WS, Hefta SA, Meyer H, Paik Y-K, Yoo J-S, Ping P, Pounds J, Adkins J, Qian X, Wang R, Wasinger V, Wu CY, Zhao X, Zeng R, Archakov A, Tsugita A, Beer I, Pandey A, Pisano M, Andrews P, Tammen H, Speicher DW, Hanash SM.   Overview of the HUPO Plasma Proteome Project:  Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database.  Proteomics 5:3226-3245, 2005.
  197. Chan DW, Colantonio DA.  Clinical Proteomics:  Cancer Diagnostics?  J. Clin. Ligand Assay 28:35-37, 2005.
  198. Zhang Z. and Chan DW.   Cancer Proteomics:  In Pursuit of "True" Biomarker  Discovery.   (Editorial).   Cancer Epidemiol. Biomarkers Prevention 14:2283-2286, 2005.
  199. Li J, Zhao J, Yu X, Lange J, Kuerer H, Krishnamurthy S, Schilling E, Khan SA, Sukumar S, Chan DW.   Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid.  Clin. Cancer Research 11:8312-20, 2005.
  200. Clarke W, Chan DW.  ProteinChips:  The essential tools for proteomic biomarker discovery and future clinical diagnostics.  (Editorial).  Clin. Chem. Lab. Med. 43:1279-1280, 2005.
  201. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE, Fung ET, Chan DW.   Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry.   Clin Chem. 12:2229-35, 2005.
  202. Song J, Patel M, Rosenzweig CN, Chan-Li Y, Sokoll LJ, Fung ET, Choi-Miura NH, Goggins M, Chan DW, Zhang Z.   Quantification of fragments of human serum inter-α-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin. Chem. 52:1045-53, 2006.
  203. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.  Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus CA19-9.  Clin. Cancer Res. 15:442-446, 2006.
  204. Hortin GL, Jortani SA, Ritchie Jr., JC, Valdes Jr., R, and Chan DW.  Proteomics:  A New Diagnostic Frontier.  Clin. Chem. 52:1218-1222, 2006.
  205. Chan DW and Shu-Ling Liang. Cancer Proteomics: New Opportunities for Old Molecules? (Editorial). Clin. Proteomics. Volume 2, Nos. 3-4, 129-132, 2006.
  206. Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH. EPCA-2: a highly specific serum marker for prostate cancer. Urology 69(4):714-20, 2007.
  207. Liang SL, Chan DW. Enzymes and related proteins as cancer biomarkers: A proteomic          approach. Clin Chim Acta. 2;381(1):93-7, 2007.
  208. Leman ES, Schoen RE, Wesissfield JL, Cannon GW, Sokoll, LJ, Chan DW, Getzenberg RH. Initial analyses of CCSA-3 and CCCSA-4 as colorectal cancer associated serum   markers. Cancer Research.  67(12): p. 5600-5605, 2007.
  209. Song J, Bai J, Yang W, Gabrielson EW, Chan DW, Zhang Z. Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer. Histopathology. 51(1):40-53, 2007.
  210. Zhang, H., and Chan DW. Cancer biomarker discovery in plasma using a tissue-targeted       proteomic approach. Cancer Epidemiology, Biomarkers and Prevention . 16:1-3, 2007.
  211. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijin HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007.
  212. Song J, Shih IeM, Salani R, Chan DW, Zhang Z. Annexin XI is associated with cisplatin      resistence and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res. 15:13(22 Pt 1):6842-9, 2007.
  213. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J,   Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T,Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L,Semmes OJ. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem. 54(1):44-52, 2008.
  214. McLerran D, Grizzle WF, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll    L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes            OJ. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem. 54(1):53-60, 2008.
  215. Leman ES, Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH. Evaluation of Colon Cancer-Specific Antigen 2 as a Potential Serum Marker for Colorectal Cancer. Clin ancer Res. 1:14(5):1349-1354, 2008.
  216. Meany DL and Chan DW. Comparability of tumor marker immunoassays: still an important             issue for clinical diagnostics? Clin Chem Lab Med 2008;46(5):575–576, 2008.
  217. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW. [-2]proPSA for prostate cancer detection: an NCI Early Detection Research Network validation  study. J Urol. 180(2):539-43, 2008.
  218. Davis GJ, Chan SS, Biegalski TT, Hemken PM, Dua R, Elliott D, Dunn W, Sokoll LJ, Chan DW, Dowell BL. Analytical performance of an automated immunoassay for tissue inhibitor of metalloproteinases-1 (TIMP-1). J Clin Ligand Assay. 30:70-76, 2008.
  219. Li Y, Sokoll LJ, Parker PE, Zhang H, Chan DW. Mass spectrometric identification of                         proteotypic peptides from clinically used tumor markers. Clin Proteomics 4:58-66, 2008.
  220. Loeb S, Chan DW, Sokoll L, Kan D, Maggiore J, Mikolajczyk SD, Mondo DM, Griffin CR, Catalona WJ. Prostate Specific Antigen Assay Standardization Bias Could Affect Clinical  Decision Making. The Journal of Urology, Vol. 180, 1959-1963, 2008.
  221. Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF, Liotta LA, Petricoin EF, Schmitt M, Semmes OJ, Söletormos G, van der Merwe E, Diamandis EP. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements; National Academy of Clinical Biochemistry. Clin Chemistry, 54(8):e1-e10, 2008.
  222. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr,Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz  R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Söletormos  G, Stephen C, Sokoll L, Hoffman BR, Diamandis EP. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chemistry, 54(12):e11-79, 2008.
  223. Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW. Glycoproteomics for Prostate Cancer Detection: Changes in Serum PSA Glycosylation Patterns. J  Proteome Res, 8(2):613-9, 2009.
  224. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE. Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. J Proteome Res. 8(1):113-117, 2009.
  225. Rosenzweig CN, Zhang Z, Sun X, Sokoll LJ, Osborne K, Partin AW, Chan DW. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J. Urology, 181(3):1407-14, 2009.
  226. Song J, Sun X, Sokoll LJ, Maki M, Tian Y, Chan DW, Zhang Z. Detection of Autoantibodies to Annexin A11 in Different Types of Human Cancer. Clinical Proteomics, 5,(2):125-131, 2009.
  227. Song J, Shih IeM, Chan DW, Zhang Z. Supression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia, (6):605-14, 2009.
  228. Loeb S, Schaeffer EM, Chan DW, Carter HB, Walsh PC, Sokoll LJ. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology, 73(5):947-9, 2009.
  229. Meany DL, Sokoll LJ, Chan DW. Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn, 3(6):597-605, 2009.
  230. Zhou J, Trock B, Tsangaris TN, Friedman NB, Shapiro D, Brotzman M, Chan-Li Y, Chan DW, Li J. A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. Breast Cancer Res Treat, 2009.
  231. Li, Y., Sokoll, L., Rush, J., Zou, N., Chan, D. W., and Zhang, H. Targeted detection of prostate cancer proteins in serum using heavy peptide standards and MALDI-TOF/TOF. Proteomics-Clinical Application. 3, 597-608, 2009.
  232.  Tian, Y., Tan, A., Sun, X., Olson, M. T., Xie, Z., Jinawath, N., Chan, DW., Shih, I, Zhang, Z., and Zhang, H. Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel treatment. Proteomics-Clinical Application.3(11), 1288-1295, 2009.
  233. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, and Chan DW. A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [-2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness. Cancer Epidemiol Biomarkers Prev., 19(5):1193-200, 2010.
  234. Chan DW. Will Cancer Proteomics Suffer from Premature Death? Clinical Proteomics, 6:1-3, 2010.

  1. Rock R.C., Chan D.W., and Perlstein M.T. Endocrine Assays in the Monitoring of Pregnancy. In: Clinics in Laboratory Medicine Vol. I, p. 157 179, W. B. Saunders, Philadelphia, 1981.
  2. Chan D.W. General Principles of Immunoassay. In: Immunoassay: A Practical Guide. D.W. Chan and M.T. Perlstein, eds. Academic Press, 1987.
  3. Chan D.W., Beveridge R.A., Rock R.C., and Walsh P.C. Overview of Immunodiagnostics for Tumor Markers. In: Ting, Chen and Schwartz, eds. Proceedings of the International Symposium on Human Tumor Markers. Amsterdam, Netherlands. 1989, pp. 277 290.
  4. Walsh P.C., Oesterling J.E., Epstein J.I., Bruzek D.J., Rock R.C. and Chan D.W. The Value of Prostate specific Antigen in the Management of Localized Prostatic Cancer. In: Murphy G. and Khoury S., eds. Therapeutic Progress in Neurological Cancer. Alan Liss, Inc. N.Y., 1989, pp. 27 33.
  5. Carter H.B., Partin A.W., Oesterling J.E., Weber J.P., Epstein J.I., Chan D.W., Rock R.C., and Walsh P.C. The use of prostate specific antigen in the management of patients with prostate cancer: The Johns Hopkins experience. In: Catalona W.J., Coffey D.S. and Karr J.P., eds. Clinical Aspects of Prostate Cancer - Assessment of New Diagnostic and Management Procedures. Elsevier, Inc., New York. 1989, pp. 247 251.
  6. Chan D.W. Recent advances in pregnancy testing. In: Lin H., Swaminathan R. and Robertshaw A. eds. Proceedings of the 4th Asian Pacific Congress of Clinical Biochemistry. Gardinar Caldwell, Ltd. Hong Kong, 1990, pp. 348 350.
  7. Chan D.W. General Introduction. In: Chan D.W., ed., Immunoassay Automation: A Practical Guide. Academic Press, San Diego, 1992, pp. 3-8.
  8. Chan D.W. Automation of Immunoassay. In: Chan D.W., ed., Immunoassay Automation: A Practical Guide. Academic Press, 1992, pp. 9-21.
  9. Chan D.W. Selection of Automated Immunoassay Systems. In: Chan D.W. ed., Immunoassay Automation: A Practical Guide. Academic Press, 1992, pp. 25-29.
  10. Chan D.W. Technical Evaluation of Automated Immunoassay Systems. In: Chan D.W., ed., Immunoassay Automation: A Practical Guide. Academic Press, 1992, pp. 31-44.
  11. Chan D.W. Clinical Evaluation of Automated Immunoassay Systems. In: Chan D.W., ed., Immunoassay Automation: A Practical Guide. Academic Press, 1992, pp. 45-53.
  12. Chan D.W. Operational Evaluation of Automated Immunoassay Systems. In: Chan D.W., ed., Immunoassay Automation: A Practical Guide. Academic Press, 1992, pp. 55-63.
  13. Chan D.W. Economical Evaluation of Automated Immunoassay Systems. In: Chan D.W., ed., Immunoassay Automation: A Practical Guide. Academic Press, 1992, pp. 65-74.
  14. Chan D.W. Overview of Automated Immunoassay Systems. In: Chan D.W., ed., Immunoassay Automation: A Practical Guide. Academic Press, 1992, pp. 77-81.
  15. Chan D.W. and Kelley C. Affinity Immunoassay System. In: Chan D.W., ed., Immunoassay Automation: A Practical Guide. Academic Press, 1992, pp. 83-94.
  16. Chan D.W. and Thornton P. AIA-1200 Immunoassay System. In: Chan D.W., ed., Immunoassay Automation: A Practical Guide, Academic Press, 1992, pp. 95-115.
  17. Chan D.W. Advances of Immunoassay in The Rapid Diagnosis of Diseases: Overview and Automation. In: Miyai K., Kanno T., and Ishikawa E., eds., Progress in Clinical Biochemistry. Elsevier Science Publishers B.V., 1992, pp. 231-234.
  18. Chan D.W. and Sell S. Tumor Markers. In: Burtis C.A. and Ashwood E.R. eds., Tietz Textbook of Clinical Chemistry, 2nd ed., W. B. Saunders, Philadelphia, 1994, pp. 897-927.
  19. Chan D.W. Clinical Implications of Free and Complexed Prostate-Specific Antigen. In: Suttajit M., Chanarat N., and Dunn F.W., eds. Proceedings of the 7th Asian-Pacific Congress of Clinical Biochemistry. Bangkok, Thailand, 1995, pp. 289-292.
  20. Chan D.W. General Introduction. In: Chan D.W. ed., Immunoassay Automation: An Updated Guide to Systems, Academic Press, San Diego, CA, 1996, pp. 1-8.
  21. Chan D.W. Summary of Automated Immunoassay Systems. In: Chan D.W. ed., Immunoassay Automation: An Updated Guide to Systems, Academic Press, San Diego, CA, 1996, pp. 9-12.
  22. Chan D.W. Immunoassay Automation: From Concept to System Performance. In: Kost G.J. ed., Handbook of Clinical Automation, Robotics, and Optimization, John Wiley & Sons, New York, 1996, pp. 419-441.
  23. Chan D.W. and Sell S. Tumor Markers. In: Burtis C.A. and Ashwood E.R. eds., Tietz Fundamentals of Clinical Chemistry, 4th ed., W. B. Saunders, Phila., 1996, pp. 336-350.
  24. Chan D.W. Automation of Immunoassays. In: Diamandis E. P. and Christopoulos T.K. eds., Immunoassay, Academic Press, San Diego, CA, 1996, pp. 483-504.
  25. Chan D.W. and Sell S. Tumor Markers. In: Burtis C.A. and Ashwood E.R. eds., Tietz Textbook of Clinical Chemistry, 3rd ed., W. B. Saunders, Philadelphia, 1999, pp.722-749.
  26. Sokoll L.J. and Chan D.W. Malignancy-Associated Endocrine Disorders. In: Jialal I., Winter W.E., Chan D.W., eds. Handbook of Diagnostic Endocrinology. AACC Press, Washington, DC, 1999, pp. 215-244.
  27. Chan D.W. and Dufour D. R. Immunoassay. In: Dufour D.R., ed. Professional Practice in Clinical Chemistry: A Companion Text. AACC Press, Washington, DC, 1999, pp. 7-1–7-15.
  28. Sokoll L.J. and Chan D.W. Tumor Markers. In: Dufour D.R., ed. Professional Practice in Clinical Chemistry: A Companion Text. AACC Press, Washington, DC, 1999, pp. 17-1–17-10.
  29. Chan D.W. and Sell S. Tumor Markers. In: Burtis C.A. and Ashwood E.R., eds., Tietz Fundamentals of Clinical Chemistry, 5th ed., W. B. Saunders, Philadelphia, 2001, pp. 390-413.
  30. Sokoll L.J. and Chan D.W. Choosing an Automated Immunoassay System. In: Wild D., ed., The Immunoassay Handbook, 2nd ed., Nature Publishing Group, London, 2001, pp. 261-265.
  31. Chan D.W. and Schwartz M.K. Tumor Markers: Introduction and General Principles. In: Diamandis E.P., Fritsche H.A., Lilja H., Chan D.W., Schwartz M.K., eds., Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications. AACC Press, Washington, DC, 2002, pp. 9-17.
  32. Shih I.-M., Sokoll L.J., and Chan D.W. Ovarian Cancer. In: Diamandis E.P., Fritsche H.A., Lilja H., Chan D.W., Schwartz M.K., eds., Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications. AACC Press, Washington, DC, 2002, pp. 239-252.
  33. Palmer-Toy D., Kuzdzal S., Chan D.W. Proteomic Approaches to Tumor Marker Discovery. In: Diamandis E.P., Fritsche H.A., Lilja H., Chan D.W., Schwartz M.K., eds., Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications. AACC Press, Washington, DC, 2002, pp. 391-400.
  34. Sokoll LJ, Chan DW.  Clinical Chemistry:  Tumor Markers.  In:  Abeloff M.D., Armitage J.O., Niederhuber J.E., Kastan M.B., and McKenna W.G., eds.   Clinical Oncology, 3rd edition, Elsevier Churchill Livingstone, Philadelphia, PA, 2004. 
  35. Clarke WA, Chan DW.  Immunochemical Methods.  In:  Ward-Cook K.M., Lehmann C.A., Schoeff L.E., Williams R.H., eds., Clinical Diagnostic Technology:  The Total Testing Process, Volume II (The Analytical Phase).  AACC Press, Washington, DC. 2005. 
  36. Sokoll LJ, Chan DW. Choosing an automated immunoassay system. In: Wild D, ed. The Immunoassay Handbook, 3rd ed. Oxford: Elsevier Ltd., 333-7, 2005.
  37. Chan, DW, Booth RA, Diamandis EP. Tumor Markers. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition, Chapter 23, 745-795, 2006. 
  38. Chan DW, Booth RA, Diamandis EP. Tumor Markers. Tietz Fundamentals of Clinical Chemistry, 6th Edition, Chapter 20, 337-362, 2008.
  39. Sokoll LJ, Chan DW.  BBiomarkers for cancer diagnostics.  In:  Abeloff M.D., Armitage J.O., Niederhuber J.E., Kastan M.B., and McKenna W.G., eds.   Clinical Oncology, 4th edition, Elsevier Churchill Livingstone, Philadelphia, PA, 2008.  pp. 277-282
  40. Sokoll LJ, Chan DW. Malignancy-associated endocrine disorders. In: Winter WE, Sokoll LJ, Jialal I, eds. Handbook of diagnostic endocrinology and metabolism, 2nd ed. Washington, DC:  AACC Press. 2008, pp.401-431.

  1. Chan D.W. and Perlstein M.T., Editors, Immunoassay: A Practical Guide, Academic Press, San Diego, CA, 1987.
  2. Chan D.W. and Perlstein M.T., Editors, Immunoassay: A Practical Guide (Chinese edition), Nuclear Press, Beijing, China, 1992.
  3. Chan D.W., Editor, Immunoassay Automation: A Practical Guide, Academic Press, San Diego, CA, 1992.
  4. Chan D.W., Editor, Immunoassay Automation: An Updated Guide to Systems, Academic Press, San Diego, CA, 1996.
  5. Jialal I., Winter W.E., Chan D.W., Editors, Handbook of Diagnostic Endocrinology, AACC Press, Washington, DC, 1999.
  6. Diamandis E.P., Fritsche H.A., Lilja H., Chan D.W., Schwartz M.K., Editors, Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications. AACC Press, Washington, DC, 2002.




  • Identification of Biomarkers For Ovarian Cancer
  • Identification of Biomarkers For breast Cancer
  • Identification of Biomarkers For Prostate Cancer
  • Biomarkers for the Detection of Pancreatic Cancer
  • A Novel Process for Biomarker Discovery and Validation Using Bioinformatics and SELDI Mass-spectrometry-based Protein Expression Profiling
  • Protein Identification and Validation of Serum Markers for Early Detection of Breast Cancer
  • Identification of Biomarkers in Breast Fluid for Breast Cancer
  • Variants of Hepcidin as Biomarker for Ovarian Cancer
  • Protein C Inhibitor (PCI) and C4a as Biomarkers for Prostate Cancer
  •  Biomarkers for Chemo-resistance in Ovarian Cancer


  • American Association for Clinical Chemistry (AACC)

  • American Association for Cancer Research (AACR)

  • National Academy of Clinical Biochemistry (NACB)

  • International Society for Enzymology (ISE) 

  • North American Chinese Clinical Chemists Association (NACCCA) 

  • Human Proteome Organization (HUPO)

  • US Human Proteome Organization (USHUPO)


Awards & Honors

  • 1968-1972 University of Oregon (Scholarship)
  • 1972-1976 State University of New York at Buffalo, Graduate Assistantship
  • 1976-1977 State University of New York at Buffalo, Postdoctoral Fellowship
  • 1983 Leadership Award - Chairman, AACC Capital Section
  • 1985 Chairman Award, NACCCA
  • 1990 Joseph Roe Award, AACC Capital Section
  • 1991 Clinical Chemist Recognition Award, AACC
  • 1992 Outstanding Speaker, AACC
  • 1996 Great Contribution to the Field of Tumor Markers, Greek Society of Tumor Marker Oncology
  • 1999 Outstanding Speaker Award, AACC
  • 2000 Distinguished Scholar Award, Chinese Journal of Laboratory Medicine, The Chinese Medical Association
  • 2001 Outstanding Contribution Award, NACCCA
  • 2004 Morton K. Schwartz Award for Significant Contributions in Cancer Research, AACC